Does increasing treatment intensity of guideline-directed medical therapy reduce the composite of death or rehospitalization in patients hospitalized for HFrEF?
In real-world practice, increasing the intensity of guideline-directed medical therapy significantly reduces death and rehospitalization after HFrEF hospitalization, yet utilization of dual and triple therapy remains low.
Background Patients hospitalized with heart failure (HF) with reduced ejection fraction have high risk of rehospitalization or death. Despite guideline recommendations based on high-quality evidence, a substantial proportion of patients with HF with reduced ejection fraction receive suboptimal care and/or do not comply with optimal care following hospitalization. Methods and Results This retrospective observational study identified 17 106 patients with HF with reduced ejection fraction with an incident HF-related hospitalization using the Humana Medicare Advantage database (2008-2016). HF medication classes (beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, or mineralocorticoid receptor antagonists) received in the year after hospitalization were recorded, and categorized by treatment intensity (ie, number of concomitant medication classes received: none 23% of patients; n=3987, monotherapy 22%; n=3777, dual therapy 41%; n=7056, or triple therapy 13%; n=2286). Compared with no medication, risk of primary outcome (composite of death or rehospitalization) was significantly reduced (hazard ratio 95% CI) with monotherapy (0.68 0.64-0.71), dual therapy (0.56 0.53-0.59), and triple therapy (0.45 0.41-0.50). Nearly half (46%) of patients who received post-discharge medication had no dose escalation. Overall, 59% of patients had follow-up with a primary care physician within 14 days of discharge, and 23% had follow-up with a cardiologist. Conclusions In real-world clinical practice, increasing treatment intensity reduced risk of death and rehospitalization among patients hospitalized for HF, though the use of guideline-recommended dual and triple HF therapy remained low. There are opportunities to improve post-discharge medical management for patients with HF with reduced ejection fraction such as optimizing dose titration and improving post-discharge follow-up with providers.
Wirtz et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: